Reeling from the deaths of two patients who took Duchenne muscular dystrophy gene therapy Elevidys, Sarepta is launching a ...

Sarepta Therapeutics is laying off 500 staffers, or 36% of its workforce, as part of a strategic restructuring aiming to save $400 million annually. | Sarepta Therapeutics has laid off 500 staffers, ...

Sarepta Therapeutics appears to have right-sized itself after laying off over a third of its staff, announcing a significant ...

Drugmaker Sarepta Therapeutics says it won’t comply with a request from U.S. regulators to halt all shipments of its gene ...

Stay up-to-date on Wall Street's latest analyst calls, stock downgrades, and upgrades for major companies like Sarepta, Cisco, and more.

Sarepta reported the deaths in March and on June 16. Both patients were teenage boys who passed away after developing acute liver failure within two months after treatment with Sarepta’s one ...

In the preceding three months, 38 analysts have released ratings for Sarepta Therapeutics SRPT, presenting a wide array of perspectives from bullish to bearish. The table below provides a concise ...

Today's biotech news features an FDA probe into the deaths tied to Sarepta's Duchenne drug, rejecting KalVista's drug application, etc.

Review Sarepta Therapeutics Inc (1SRPT:XMIL) stock and the current sustainability and ESG risk rating to help with your investing decisions.

Sarepta Therapeutics, Inc. (NASDAQ: SRPT) is one of the 10 Worst Aggressive Growth Stocks to Buy According to Short Sellers. On June 18, TD Cowen downgraded Sarepta Therapeutics, Inc. (NASDAQ:SRPT ...

In June, Sarepta reported a second death in a patient who had received its gene therapy, which raised concerns about the safety and future demand for the treatment. Both boys were non-ambulatory ...